JP2003525018A - 非内在性の構成的に活性化されるヒトｇタンパク質共役型受容体 - Google Patents
非内在性の構成的に活性化されるヒトｇタンパク質共役型受容体Info
- Publication number
- JP2003525018A JP2003525018A JP2000576021A JP2000576021A JP2003525018A JP 2003525018 A JP2003525018 A JP 2003525018A JP 2000576021 A JP2000576021 A JP 2000576021A JP 2000576021 A JP2000576021 A JP 2000576021A JP 2003525018 A JP2003525018 A JP 2003525018A
- Authority
- JP
- Japan
- Prior art keywords
- endogenous
- protein
- cdna
- plasmid
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000005962 receptors Human genes 0.000 title claims abstract description 187
- 108020003175 receptors Proteins 0.000 title claims abstract description 187
- 101000887490 Homo sapiens Guanine nucleotide-binding protein G(z) subunit alpha Proteins 0.000 title claims abstract description 44
- 102000052301 human GNAZ Human genes 0.000 title claims abstract description 44
- 239000002299 complementary DNA Substances 0.000 claims description 88
- 239000013612 plasmid Substances 0.000 claims description 57
- 239000013598 vector Substances 0.000 claims description 52
- 101100230509 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) hat-1 gene Proteins 0.000 claims 3
- 101000743541 Homo sapiens Vomeronasal type-1 receptor 4 Proteins 0.000 claims 1
- 102100038327 Vomeronasal type-1 receptor 4 Human genes 0.000 claims 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 abstract description 111
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 abstract description 111
- 239000006274 endogenous ligand Substances 0.000 abstract description 20
- 108091008880 orphan GPCRs Proteins 0.000 abstract description 7
- 230000037011 constitutive activity Effects 0.000 abstract description 6
- 102000027257 transmembrane receptors Human genes 0.000 abstract description 2
- 108091008578 transmembrane receptors Proteins 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 73
- 150000001875 compounds Chemical class 0.000 description 70
- 239000013615 primer Substances 0.000 description 63
- 238000003556 assay Methods 0.000 description 62
- 108091006027 G proteins Proteins 0.000 description 44
- 102000030782 GTP binding Human genes 0.000 description 44
- 108091000058 GTP-Binding Proteins 0.000 description 44
- 239000012634 fragment Substances 0.000 description 40
- 238000000034 method Methods 0.000 description 35
- 239000012528 membrane Substances 0.000 description 33
- 108090000623 proteins and genes Proteins 0.000 description 32
- 108020001507 fusion proteins Proteins 0.000 description 28
- XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 description 28
- 102000037865 fusion proteins Human genes 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 26
- 239000000872 buffer Substances 0.000 description 25
- 230000035772 mutation Effects 0.000 description 25
- 238000012216 screening Methods 0.000 description 24
- 239000000556 agonist Substances 0.000 description 23
- 150000001413 amino acids Chemical class 0.000 description 23
- 230000027455 binding Effects 0.000 description 23
- 230000000692 anti-sense effect Effects 0.000 description 22
- 238000013459 approach Methods 0.000 description 22
- 239000003814 drug Substances 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 19
- 238000001514 detection method Methods 0.000 description 18
- 101000738506 Homo sapiens Psychosine receptor Proteins 0.000 description 17
- 239000012148 binding buffer Substances 0.000 description 17
- 239000003446 ligand Substances 0.000 description 17
- 150000007523 nucleic acids Chemical class 0.000 description 17
- 102100037860 Psychosine receptor Human genes 0.000 description 16
- 230000004913 activation Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 230000003834 intracellular effect Effects 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 16
- 238000001890 transfection Methods 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 12
- 239000007995 HEPES buffer Substances 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 238000002703 mutagenesis Methods 0.000 description 12
- 231100000350 mutagenesis Toxicity 0.000 description 12
- 239000004031 partial agonist Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 239000012679 serum free medium Substances 0.000 description 12
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 11
- 102000018697 Membrane Proteins Human genes 0.000 description 11
- 108010052285 Membrane Proteins Proteins 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 239000013604 expression vector Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 10
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 102000030621 adenylate cyclase Human genes 0.000 description 9
- 108060000200 adenylate cyclase Proteins 0.000 description 9
- 239000007853 buffer solution Substances 0.000 description 9
- 230000006552 constitutive activation Effects 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 239000008188 pellet Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 8
- 239000013613 expression plasmid Substances 0.000 description 8
- 102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 238000005227 gel permeation chromatography Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 125000006850 spacer group Chemical group 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108060001084 Luciferase Proteins 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 239000012131 assay buffer Substances 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000000265 homogenisation Methods 0.000 description 6
- 229960000367 inositol Drugs 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 101710095468 Cyclase Proteins 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101000690425 Homo sapiens Type-1 angiotensin II receptor Proteins 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 108091081024 Start codon Proteins 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 4
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 4
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 4
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 4
- 102000016978 Orphan receptors Human genes 0.000 description 4
- 108070000031 Orphan receptors Proteins 0.000 description 4
- 102000014384 Type C Phospholipases Human genes 0.000 description 4
- 108010079194 Type C Phospholipases Proteins 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 4
- 239000000700 radioactive tracer Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 102000004420 Creatine Kinase Human genes 0.000 description 3
- 108010042126 Creatine kinase Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010005415 G2A receptor Proteins 0.000 description 3
- 108091006065 Gs proteins Proteins 0.000 description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 3
- 101001132878 Homo sapiens Motilin receptor Proteins 0.000 description 3
- 102100033374 Leukotriene B4 receptor 1 Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100033818 Motilin receptor Human genes 0.000 description 3
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 3
- 108091027981 Response element Proteins 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 108010062475 Type 2 Angiotensin Receptor Proteins 0.000 description 3
- 102100040372 Type-2 angiotensin II receptor Human genes 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 230000001351 cycling effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000018 receptor agonist Substances 0.000 description 3
- 229940044601 receptor agonist Drugs 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 2
- 108091006109 GTPases Proteins 0.000 description 2
- 108010001515 Galectin 4 Proteins 0.000 description 2
- 102100039556 Galectin-4 Human genes 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 101001017968 Homo sapiens Leukotriene B4 receptor 1 Proteins 0.000 description 2
- -1 MC4 nucleic acid Chemical class 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000012911 assay medium Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 150000001982 diacylglycerols Chemical class 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000031146 intracellular signal transduction Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229950007002 phosphocreatine Drugs 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 239000012557 regeneration buffer Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- MMWCIQZXVOZEGG-UHFFFAOYSA-N 1,4,5-IP3 Natural products OC1C(O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(O)C1OP(O)(O)=O MMWCIQZXVOZEGG-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- KDRNOBUWMVLVFH-UHFFFAOYSA-N 2-methyl-n-(2,2,6,6-tetramethylpiperidin-4-yl)prop-2-enamide Chemical compound CC(=C)C(=O)NC1CC(C)(C)NC(C)(C)C1 KDRNOBUWMVLVFH-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- MMWCIQZXVOZEGG-XJTPDSDZSA-N D-myo-Inositol 1,4,5-trisphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@@H]1OP(O)(O)=O MMWCIQZXVOZEGG-XJTPDSDZSA-N 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102100036738 Guanine nucleotide-binding protein subunit alpha-11 Human genes 0.000 description 1
- 108091006066 Gzα proteins Proteins 0.000 description 1
- 101100283445 Homo sapiens GNA11 gene Proteins 0.000 description 1
- 101001116388 Homo sapiens Melatonin-related receptor Proteins 0.000 description 1
- 101000740112 Homo sapiens Membrane-associated transporter protein Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108090000093 Leukotriene B4 receptors Proteins 0.000 description 1
- 102100037258 Membrane-associated transporter protein Human genes 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 101100015376 Rattus norvegicus Gnaz gene Proteins 0.000 description 1
- 101000633010 Rattus norvegicus Somatostatin Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 241000566107 Scolopax Species 0.000 description 1
- 239000004280 Sodium formate Substances 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108010062481 Type 1 Angiotensin Receptor Proteins 0.000 description 1
- 102100026803 Type-1 angiotensin II receptor Human genes 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229960001456 adenosine triphosphate Drugs 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000002809 confirmatory assay Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012912 drug discovery process Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 102000048033 human GPR65 Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 1
- 229960005417 ketanserin Drugs 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
- 235000019254 sodium formate Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (65)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/170,496 US6555339B1 (en) | 1997-04-14 | 1998-10-13 | Non-endogenous, constitutively activated human protein-coupled receptors |
| US09/170,496 | 1998-10-13 | ||
| US10802998P | 1998-11-12 | 1998-11-12 | |
| US60/108,029 | 1998-11-12 | ||
| US10921398P | 1998-11-20 | 1998-11-20 | |
| US60/109,213 | 1998-11-20 | ||
| US11006098P | 1998-11-27 | 1998-11-27 | |
| US60/110,060 | 1998-11-27 | ||
| US12041699P | 1999-02-16 | 1999-02-16 | |
| US60/120,416 | 1999-02-16 | ||
| US12185299P | 1999-02-26 | 1999-02-26 | |
| US60/121,852 | 1999-02-26 | ||
| US12394999P | 1999-03-12 | 1999-03-12 | |
| US12394699P | 1999-03-12 | 1999-03-12 | |
| US12395199P | 1999-03-12 | 1999-03-12 | |
| US12394499P | 1999-03-12 | 1999-03-12 | |
| US12394899P | 1999-03-12 | 1999-03-12 | |
| US12394599P | 1999-03-12 | 1999-03-12 | |
| US60/123,946 | 1999-03-12 | ||
| US60/123,948 | 1999-03-12 | ||
| US60/123,945 | 1999-03-12 | ||
| US60/123,944 | 1999-03-12 | ||
| US60/123,951 | 1999-03-12 | ||
| US60/123,949 | 1999-03-12 | ||
| US13643799P | 1999-05-28 | 1999-05-28 | |
| US13756799P | 1999-05-28 | 1999-05-28 | |
| US13643699P | 1999-05-28 | 1999-05-28 | |
| US13643999P | 1999-05-28 | 1999-05-28 | |
| US13712799P | 1999-05-28 | 1999-05-28 | |
| US13713199P | 1999-05-28 | 1999-05-28 | |
| US60/137,131 | 1999-05-28 | ||
| US60/137,127 | 1999-05-28 | ||
| US60/136,437 | 1999-05-28 | ||
| US60/136,436 | 1999-05-28 | ||
| US60/136,439 | 1999-05-28 | ||
| US60/137,567 | 1999-05-28 | ||
| US60/141,448 | 1999-06-29 | ||
| US14144899A | 1999-06-30 | 1999-06-30 | |
| US15111499P | 1999-08-27 | 1999-08-27 | |
| US60/151,114 | 1999-08-27 | ||
| US15252499P | 1999-09-03 | 1999-09-03 | |
| US60/152,524 | 1999-09-03 | ||
| US15665399A | 1999-09-09 | 1999-09-09 | |
| US15663399P | 1999-09-29 | 1999-09-29 | |
| US15655599P | 1999-09-29 | 1999-09-29 | |
| US15663499P | 1999-09-29 | 1999-09-29 | |
| US60/156,633 | 1999-09-29 | ||
| US60/156,653 | 1999-09-29 | ||
| US60/156,555 | 1999-09-29 | ||
| US60/156,634 | 1999-09-29 | ||
| US15728299P | 1999-10-01 | 1999-10-01 | |
| US15728099P | 1999-10-01 | 1999-10-01 | |
| US15729399P | 1999-10-01 | 1999-10-01 | |
| US15729499P | 1999-10-01 | 1999-10-01 | |
| US15728199P | 1999-10-01 | 1999-10-01 | |
| US60/157,294 | 1999-10-01 | ||
| US60/157,282 | 1999-10-01 | ||
| US60/157,281 | 1999-10-01 | ||
| US60/157,293 | 1999-10-01 | ||
| US60/157,280 | 1999-10-01 | ||
| US41704499A | 1999-10-12 | 1999-10-12 | |
| US41676099A | 1999-10-12 | 1999-10-12 | |
| US09/417,044 | 1999-10-12 | ||
| US09/416,760 | 1999-10-12 | ||
| PCT/US1999/024065 WO2000022131A2 (en) | 1998-10-13 | 1999-10-13 | Non-endogenous, constitutively activated human g protein-coupled receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010000087A Division JP2010142235A (ja) | 1998-10-13 | 2010-01-04 | 非内在性の構成的に活性化されるヒトｇタンパク質共役型受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003525018A true JP2003525018A (ja) | 2003-08-26 |
| JP2003525018A6 JP2003525018A6 (ja) | 2004-07-08 |
| JP2003525018A5 JP2003525018A5 (enExample) | 2006-11-09 |
Family
ID=27792453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000576021A Withdrawn JP2003525018A (ja) | 1998-10-13 | 1999-10-13 | 非内在性の構成的に活性化されるヒトｇタンパク質共役型受容体 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2003525018A (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003521894A (ja) * | 1999-09-24 | 2003-07-22 | ソルベイ・フアーマシユーチカルズ・ベー・ブイ | 新規のヒトｇ−タンパク質共役型受容体 |
-
1999
- 1999-10-13 JP JP2000576021A patent/JP2003525018A/ja not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003521894A (ja) * | 1999-09-24 | 2003-07-22 | ソルベイ・フアーマシユーチカルズ・ベー・ブイ | 新規のヒトｇ−タンパク質共役型受容体 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4672866B2 (ja) | 非内因性の構成的に活性化されたヒトｇタンパク質共役受容体 | |
| AU2005244540B2 (en) | Endogenous and non-endogenous versions of human G protein-coupled receptors | |
| JP2003532057A (ja) | 非内因性の、構成的に活性化される既知ｇタンパク質−共役受容体 | |
| JP2003534767A (ja) | ヒトオーファンｇタンパク質共役型受容体 | |
| KR20010080882A (ko) | 구성적으로 활성화된 비내생성 인간 ｇ 단백질 결합형수용체 | |
| JP2010166925A (ja) | ヒトｇタンパク質共役レセプターの内因性バージョンおよび非内因性バージョン | |
| JP2004526441A (ja) | 内因性および非内因性型ヒトｇタンパク質共役受容体 | |
| US20130165633A1 (en) | Endogenous and Non-Endogenous Versions of Human G Protein-Coupled Receptors | |
| US20130309766A1 (en) | Endogenous and Non-Endogenous Versions of Human G Protein-Coupled Receptors | |
| JP2003525018A (ja) | 非内在性の構成的に活性化されるヒトｇタンパク質共役型受容体 | |
| US8440391B2 (en) | Constitutively activated human G protein coupled receptors | |
| JP4768946B2 (ja) | ヒトｇタンパク質共役型受容体の内因性および非内因性型 | |
| JP2003525018A6 (ja) | 非内在性の構成的に活性化されるヒトｇタンパク質共役型受容体 | |
| JP2010263909A (ja) | 非内在性の構成的に活性化されるヒトｇタンパク質共役型受容体 | |
| JP2010142235A (ja) | 非内在性の構成的に活性化されるヒトｇタンパク質共役型受容体 | |
| US20070072248A1 (en) | Constitutively activated human G protein coupled receptors | |
| US20100317046A1 (en) | Non-Endogenous, Constitutively Activated Versions of Human G Protein Coupled Receptor: FSHR | |
| AU6299199A (en) | Non-endogenous, constitutively activated human g protein-coupled receptors | |
| EP1676861A2 (en) | Non-endogenous, constitutively activated human G protein-coupled receptors | |
| US20150153327A1 (en) | Endogenous and Non-Endogenous Versions of Human G Protein-Coupled Receptors | |
| JP2011097950A (ja) | ヒトｇタンパク質共役型受容体の内因性および非内因性型 | |
| HK1091214A (en) | Non-endogenous, constitutively activated human g protein-coupled receptors | |
| EP1137776A2 (en) | Non-endogenous, constitutively activated human g protein-coupled receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050628 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050628 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060925 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080213 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080418 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080425 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080813 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090206 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090501 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090513 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090605 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090612 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090703 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090710 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090806 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090806 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090831 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100104 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100118 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20100212 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20111017 |